Stay updated on Rilzabrutinib for CSU: H1 Resistant - Clinical Trial

Sign up to get notified when there's something new on the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    A notice about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The study record itself remains unavailable behind a 403 error.
    Difference
    1%
    Check dated 2026-10-20T22:50:20.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-06T23:10:13.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    A 403 Forbidden error page appears when attempting to view the study record, showing a 403 message. A Home button is present, indicating restricted access rather than the study content.
    Difference
    17%
    Check dated 2026-09-22T23:55:52.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The page's revision label has updated from v3.6.6 to v3.7.0, indicating a newer release of the page template/system without altering study content.
    Difference
    0.0%
    Check dated 2026-09-16T00:10:26.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    A new revision line 'Revision: v3.6.6' was added and the previous 'Revision: v3.6.5' was removed, updating the page's revision history.
    Difference
    0.0%
    Check dated 2026-09-01T19:01:02.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    On 2026-08-06, the study record adds a Results Posted entry and updates the open-label extension to allow either dose B or dose C with specified follow-up weeks. Enrollment is listed as 160, and several secondary outcomes and eligibility details have been revised to reflect the new design and reporting status.
    Difference
    1%
    Check dated 2026-08-11T19:51:00.000Z thumbnail image

Stay in the know with updates to Rilzabrutinib for CSU: H1 Resistant - Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page.